JP7752675B2 - ウイルスに対するタウロリジンの使用 - Google Patents

ウイルスに対するタウロリジンの使用

Info

Publication number
JP7752675B2
JP7752675B2 JP2023501231A JP2023501231A JP7752675B2 JP 7752675 B2 JP7752675 B2 JP 7752675B2 JP 2023501231 A JP2023501231 A JP 2023501231A JP 2023501231 A JP2023501231 A JP 2023501231A JP 7752675 B2 JP7752675 B2 JP 7752675B2
Authority
JP
Japan
Prior art keywords
virus
taurolidine
cells
infection
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023501231A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533041A (ja
JPWO2022007713A5 (https=
JP2023533041A5 (https=
Inventor
ユイウェイ カオ
ユアンクオ リー
チャオシアン リュ
ソン リー
ハイヤン シアン
ウー チョン
ティエチョン ワン
ウェイヤン スン
シュエフォン ワン
ポー チョウ
エンタオ リー
ナー フォン
ヨンクン チャオ
ソンタオ ヤン
チョン スー
シエンチュー シア
Original Assignee
アカデミー オブ ミリタリー メディカル サイエンシズ
チャンチュン メイリング バイオロジカル エンジニアリング カンパニー，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010639186.0A external-priority patent/CN111773227A/zh
Priority claimed from CN202010638926.9A external-priority patent/CN111658652A/zh
Priority claimed from CN202010994928.1A external-priority patent/CN112641789A/zh
Application filed by アカデミー オブ ミリタリー メディカル サイエンシズ, チャンチュン メイリング バイオロジカル エンジニアリング カンパニー，リミティド filed Critical アカデミー オブ ミリタリー メディカル サイエンシズ
Publication of JP2023533041A publication Critical patent/JP2023533041A/ja
Publication of JPWO2022007713A5 publication Critical patent/JPWO2022007713A5/ja
Publication of JP2023533041A5 publication Critical patent/JP2023533041A5/ja
Application granted granted Critical
Publication of JP7752675B2 publication Critical patent/JP7752675B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023501231A 2020-07-06 2021-07-02 ウイルスに対するタウロリジンの使用 Active JP7752675B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202010639186.0A CN111773227A (zh) 2020-07-06 2020-07-06 牛磺罗定在制备抗新型冠状病毒SARS-CoV-2药物中的应用
CN202010639186.0 2020-07-06
CN202010638926.9A CN111658652A (zh) 2020-07-06 2020-07-06 牛磺罗定在制备抗冠状病毒药物中的应用
CN202010638926.9 2020-07-06
CN202010994928.1A CN112641789A (zh) 2020-09-21 2020-09-21 一种化合物在治疗和预防新型冠状病毒和流感病毒药物方面的应用
CN202010994928.1 2020-09-21
PCT/CN2021/104197 WO2022007713A1 (zh) 2020-07-06 2021-07-02 牛磺罗定在抗病毒中的应用

Publications (4)

Publication Number Publication Date
JP2023533041A JP2023533041A (ja) 2023-08-01
JPWO2022007713A5 JPWO2022007713A5 (https=) 2023-11-22
JP2023533041A5 JP2023533041A5 (https=) 2023-11-22
JP7752675B2 true JP7752675B2 (ja) 2025-10-10

Family

ID=77998103

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501231A Active JP7752675B2 (ja) 2020-07-06 2021-07-02 ウイルスに対するタウロリジンの使用

Country Status (4)

Country Link
JP (1) JP7752675B2 (https=)
CN (1) CN113491700B (https=)
BR (1) BR112023000308A2 (https=)
WO (1) WO2022007713A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114917285B (zh) * 2022-04-06 2023-06-23 军事科学院军事医学研究院军事兽医研究所 一种多糖化合物在预防和治疗呼吸道病毒感染药物中的应用
CN115350181B (zh) * 2022-08-17 2023-12-29 吉林大学 一种小分子化合物在制备抗病毒感染的药物中的应用
CN117503777A (zh) * 2023-03-17 2024-02-06 中国人民解放军军事科学院军事医学研究院 化合物在抗病毒中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140113881A1 (en) 2011-06-10 2014-04-24 Johannes Reinmuller Antiinfective composition
US20160159759A1 (en) 2012-06-18 2016-06-09 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents
JP2020040964A (ja) 2014-12-19 2020-03-19 ガイストリッヒ・ファルマ・アーゲーＧｅｉｓｔｌｉｃｈ Ｐｈａｒｍａ Ａｇ オキサチアジン様化合物を作製する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608051B1 (en) * 1999-03-12 2003-08-19 Medpointe Healthcare Inc. Compositions and methods for treating blood
US6302108B1 (en) * 2000-03-10 2001-10-16 Carter-Wallace, Inc Spermicidal and viricidal compositions
EP2699572B1 (en) * 2011-04-21 2016-08-10 Origenis GmbH Heterocyclic compounds as kinase inhibitors
WO2017040655A1 (en) * 2015-08-31 2017-03-09 Cormedix Inc. Delivery of active agents using nanofiber webs
CN111773227A (zh) * 2020-07-06 2020-10-16 长春迈灵生物工程有限公司 牛磺罗定在制备抗新型冠状病毒SARS-CoV-2药物中的应用
CN112641789A (zh) * 2020-09-21 2021-04-13 军事科学院军事医学研究院军事兽医研究所 一种化合物在治疗和预防新型冠状病毒和流感病毒药物方面的应用
CN111617086A (zh) * 2020-07-06 2020-09-04 长春迈灵生物工程有限公司 牛磺罗定在制备抗hpv病毒药物中的应用
CN111658652A (zh) * 2020-07-06 2020-09-15 长春迈灵生物工程有限公司 牛磺罗定在制备抗冠状病毒药物中的应用
CN111671758A (zh) * 2020-07-06 2020-09-18 长春迈灵生物工程有限公司 牛磺罗定在制备抗hiv病毒药物中的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140113881A1 (en) 2011-06-10 2014-04-24 Johannes Reinmuller Antiinfective composition
US20160159759A1 (en) 2012-06-18 2016-06-09 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents
JP2020040964A (ja) 2014-12-19 2020-03-19 ガイストリッヒ・ファルマ・アーゲーＧｅｉｓｔｌｉｃｈ Ｐｈａｒｍａ Ａｇ オキサチアジン様化合物を作製する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mezoff, Ethan A et al，Heightened Central Line-associated Blood Stream Infection Risk During a Pandemic，Journal of pediatric gastroenterology and nutrition ，2020年06月02日，70,6，e140-e141

Also Published As

Publication number Publication date
CN113491700B (zh) 2023-03-28
CN113491700A (zh) 2021-10-12
JP2023533041A (ja) 2023-08-01
WO2022007713A1 (zh) 2022-01-13
BR112023000308A2 (pt) 2023-03-28

Similar Documents

Publication Publication Date Title
CN110325187B (zh) N-氨基甲酰亚胺基-5-(1-甲基-1h-吡唑-4-基)-2-萘甲酰胺在制备治疗流感的药物中的用途
JP7752675B2 (ja) ウイルスに対するタウロリジンの使用
KR101440629B1 (ko) 바이러스 감염을 시스테아민 화합물로 치료하는 물질들 및방법들
CN106668002A (zh) 芦竹碱及其衍生物在制备抗7型腺病毒药物中的应用
CN112546038A (zh) 杨梅素在制备预防或治疗冠状病毒、流感病毒的药物中的应用
CN112641789A (zh) 一种化合物在治疗和预防新型冠状病毒和流感病毒药物方面的应用
CN114748466B (zh) Napyradiomycin类化合物在制备猪伪狂犬病病毒抑制剂中的应用
US11433080B2 (en) Antiviral treatment
CN113101283B (zh) 一种多苯环共轭分子在制备抗病毒药物中的用途及抗病毒药物
CN112843043A (zh) 盐霉素在制备抗冠状病毒药物中的应用
CN113143924B (zh) 硫代咪唑烷酮药物在治疗covid-19疾病中的用途
CN109432106B (zh) 一种复方磺胺氯哒嗪及其制备方法
TWI764284B (zh) 使用喹啉化合物來對抗冠狀病毒感染的方法
WO2021215938A1 (en) Anti-viral methods and compositions
CN113197912B (zh) 异戊酰螺旋霉素类化合物及其组合物在制备抗病毒药物中的应用
CN117503777A (zh) 化合物在抗病毒中的应用
TWI792325B (zh) 使用香豆素-衍生的化合物來對抗冠狀病毒感染的方法
RU2842052C1 (ru) Азеластин в качестве противовирусного лечения
CN117122599B (zh) 氯法齐明在制备预防和/或治疗猪流行性腹泻病毒感染的药物中的应用
US7282599B2 (en) Dithiocarbamate antiviral agents and methods of using same
CN109999026B (zh) 一种噻吩甲酰胺类化合物在制备抗口蹄疫药物中的应用
CN109550041B (zh) 奥利万星磷酸盐在制备防治牛传染性鼻气管炎药物中的应用
CN102112461B (zh) 新型二芳基庚酮系化合物及其应用
CN121648127A (zh) 芳基取代嘧啶腙类化合物在制备抗流感病毒药物中的应用
EA046313B1 (ru) Лекарственные формы терапевтических препаратов от гриппа

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250602

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250909

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250930

R150 Certificate of patent or registration of utility model

Ref document number: 7752675

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150